Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
124 studies found for:    "Pneumonia, Bacterial"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
Condition: Pneumonia, Bacterial
Intervention: Drug: daptomycin
2 Completed A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
Condition: Pneumonia, Bacterial
Interventions: Drug: Ceftriaxone;   Drug: beta-lactam
3 Recruiting A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia
Condition: Pneumonia, Bacterial
Intervention: Drug: ME1100 inhalation solution
4 Completed Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae
Condition: Pneumonia, Bacterial
Intervention: Drug: daptomycin
5 Completed Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia
Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin fosfomycin inhalation solution;   Drug: Aerosolized placebo
6 Completed Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
Condition: Community-Acquired Bacterial Pneumonia
Interventions: Drug: Levofloxacin;   Drug: CEM-101
7 Completed
Has Results
Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia
Conditions: Pneumonia, Bacterial;   Community-acquired
Interventions: Drug: Ceftaroline;   Drug: Levofloxacin
8 Completed Five Versus Seven Day Antibiotic Course for the Treatment of Pneumonia in the Intensive Care Unit
Condition: Pneumonia, Bacterial
Interventions: Other: 5 Days of Antibiotics;   Other: 7 Days of Antibiotics therapy for pneumonia
9 Recruiting Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
Condition: Bacterial Pneumonia
Interventions: Drug: Imipenem;   Drug: Relebactam;   Drug: Cilastatin;   Drug: Piperacillin;   Drug: Tazobactam;   Drug: Linezolid
10 Terminated Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia
Condition: Community-Acquired Bacterial Pneumonia (CABP)
Interventions: Drug: JNJ-32729463;   Drug: moxifloxacin;   Drug: JNJ-32729463 (Open-Label)
11 Completed
Has Results
A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
Conditions: Community-Acquired Bacterial Pneumonia;   Lung Infection of Individual Not Recently Hospitalized
Interventions: Drug: Ceftaroline;   Drug: Ceftriaxone
12 Recruiting Safety and Efficacy of Solithromycin in Adolescents and Children With Community-acquired Bacterial Pneumonia
Condition: Community-acquired Bacterial Pneumonia
Interventions: Drug: Solithromycin;   Drug: Standard of Care
13 Completed Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
Condition: Community-acquired Bacterial Pneumonia
Interventions: Drug: Solithromycin;   Drug: Moxifloxacin;   Other: Placebo to match solithromycin
14 Completed Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
Condition: Community-acquired Bacterial Pneumonia
Interventions: Drug: Solithromycin;   Drug: Moxifloxacin
15 Withdrawn Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia
Condition: Community-Acquired Bacterial Pneumonia (CABP)
Intervention: Drug: Ceftaroline fosamil
16 Completed
Has Results
The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)
Condition: Pneumonia, Bacterial
Intervention: Drug: ampicillin sodium/sulbactam sodium
17 Withdrawn Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization
Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Fosfomycin Inhalation Solution;   Drug: Aerosolized placebo
18 Recruiting Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Inhalation Solution (BAY41-6551);   Drug: Aerosolized Placebo
19 Recruiting Inhaled Amikacin Solution (BAY 41-6551) as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Inhalation Solution (BAY41-6551);   Drug: Aerosolized Placebo
20 Completed
Has Results
A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
Condition: Pneumonia, Bacterial
Interventions: Drug: sulopenem and PF-03709270;   Drug: Sulopenem and PF-03709270;   Drug: Ceftriaxone and amoxicillin/clavulanate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.